These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 26316575)

  • 1. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
    van der Heijde D; Joshi A; Pangan AL; Chen N; Betts K; Mittal M; Bao Y
    Rheumatology (Oxford); 2016 Jan; 55(1):80-8. PubMed ID: 26316575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study.
    Dougados M; van der Heijde D; Tsai WC; Saaibi D; Marshall L; Jones H; Pedersen R; Vlahos B; Tarallo M
    Health Qual Life Outcomes; 2020 Jan; 18(1):4. PubMed ID: 31900174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
    Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
    Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.
    Navarro-Compán V; Ramiro S; Deodhar A; Mease PJ; Rudwaleit M; de la Loge C; Fleurinck C; Taieb V; Mørup MF; Massow U; Kay J; Magrey M
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.
    van der Heijde D; Sieper J; Maksymowych WP; Lambert RG; Chen S; Hojnik M; Anderson JK; Pangan AL
    Arthritis Res Ther; 2018 Mar; 20(1):61. PubMed ID: 29587851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis.
    Dougados M; Tsai WC; Saaibi DL; Bonin R; Bukowski J; Pedersen R; Vlahos B; Kotak S
    J Rheumatol; 2015 Oct; 42(10):1835-41. PubMed ID: 26276968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
    J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
    Osterhaus JT; Purcaru O
    Arthritis Res Ther; 2014 Aug; 16(4):R164. PubMed ID: 25099160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
    Kilic E; Kilic G; Akgul O; Ozgocmen S
    Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of etanercept in patients from Latin America, Central Europe and Asia with early non-radiographic axial spondyloarthritis.
    Wei JC; Tsai WC; Citera G; Kotak S; Llamado L
    Int J Rheum Dis; 2018 Jul; 21(7):1443-1451. PubMed ID: 27863065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.
    Sieper J; Landewé R; Magrey M; Anderson JK; Zhong S; Wang X; Lertratanakul A
    RMD Open; 2019; 5(1):e000917. PubMed ID: 31245052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
    Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
    J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
    Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis.
    Dougados M; Wood E; Gossec L; Dubanchet A; Logeart I; van der Heijde D
    J Rheumatol; 2015 Dec; 42(12):2361-8. PubMed ID: 26568588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort).
    van Lunteren M; Ez-Zaitouni Z; Fongen C; Landewé R; Ramonda R; van der Heijde D; van Gaalen FA
    Rheumatology (Oxford); 2017 Dec; 56(12):2222-2228. PubMed ID: 29155961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.
    Haibel H; Rudwaleit M; Listing J; Heldmann F; Wong RL; Kupper H; Braun J; Sieper J
    Arthritis Rheum; 2008 Jul; 58(7):1981-91. PubMed ID: 18576337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
    Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
    Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.